FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2971183932> ?p ?o ?g. }

• W2971183932 endingPage "211" @default.
• W2971183932 startingPage "211" @default.
• W2971183932 abstract "To compare the efficacy and safety of imatinib and cytarabine (ara-c) combination versus imatinib monotherapy in newly diagnosed patients with chronic phase chronic myeloid leukemia (CML-CP).This prospective, randomized study included adult patients (age >18 years) with newly diagnosed CML-CP. Patients received either a single oral dose of imatinib 400 mg/day in combination with a subcutaneous injection of ara-c 20 mg/m2/day (imatinib + ara-c) or a single oral dose of imatinib 400 mg/day. Primary endpoints were hematological and molecular responses at 3 months and cytogenetic responses at 6 and 12 months. Secondary endpoints included grade 3/4 hematological and nonhematological adverse events (AEs).Of 30 patients included, 14 were randomized to imatinib + ara-c and 16 to imatinib alone. Complete hematologic response (CHR) at 3 months was higher with imatinib + ara-c vs. imatinib alone (100% vs. 87.5%, P = 0.48). The median time to achieve CHR was significantly (P < 0.001) lower with imatinib + ara-c (32.07 vs. 23.43 days). Molecular response at 3 months was significantly higher (P = 0.04) with imatinib + ara-c vs. imatinib alone (100% vs. 68.75%). Complete cytogenetic response was also higher with imatinib + ara-c vs. imatinib alone (42.85% vs. 25% at 6 months and 71.4% vs. 62.5% at 12 months). Neutropenia followed by thrombocytopenia and anemia were the most common AEs. Grade 3/4 hematological and nausea events were significantly (P < 0.05) higher with imatinib + ara-c. Other nonhematological events were not significantly different between the treatments. The median follow-up duration was 20 months (range: 15-23 months).Imatinib with low-dose ara-c can be considered as a potential first-line treatment option for CML-CP." @default.
• W2971183932 created "2019-09-05" @default.
• W2971183932 creator A5008224705 @default.
• W2971183932 creator A5049660528 @default.
• W2971183932 creator A5059502961 @default.
• W2971183932 date "2019-01-01" @default.
• W2971183932 modified "2023-10-02" @default.
• W2971183932 title "A prospective, randomized study to compare the combination of imatinib and cytarabine versus imatinib alone in newly diagnosed patients with chronic phase chronic myeloid leukemia" @default.
• W2971183932 cites W120676909 @default.
• W2971183932 cites W1968747503 @default.
• W2971183932 cites W1987239635 @default.
• W2971183932 cites W1992798892 @default.
• W2971183932 cites W2016960626 @default.
• W2971183932 cites W2028669471 @default.
• W2971183932 cites W2058071703 @default.
• W2971183932 cites W2080060037 @default.
• W2971183932 cites W2098047889 @default.
• W2971183932 cites W2109163020 @default.
• W2971183932 cites W2117806883 @default.
• W2971183932 cites W2166654361 @default.
• W2971183932 cites W2587781815 @default.
• W2971183932 doi "https://doi.org/10.4103/ijc.ijc_303_18" @default.
• W2971183932 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31389383" @default.
• W2971183932 hasPublicationYear "2019" @default.
• W2971183932 type Work @default.
• W2971183932 sameAs 2971183932 @default.
• W2971183932 citedByCount "4" @default.
• W2971183932 countsByYear W29711839322022 @default.
• W2971183932 countsByYear W29711839322023 @default.
• W2971183932 crossrefType "journal-article" @default.
• W2971183932 hasAuthorship W2971183932A5008224705 @default.
• W2971183932 hasAuthorship W2971183932A5049660528 @default.
• W2971183932 hasAuthorship W2971183932A5059502961 @default.
• W2971183932 hasConcept C126322002 @default.
• W2971183932 hasConcept C143998085 @default.
• W2971183932 hasConcept C168563851 @default.
• W2971183932 hasConcept C197934379 @default.
• W2971183932 hasConcept C203092338 @default.
• W2971183932 hasConcept C2776694085 @default.
• W2971183932 hasConcept C2777063308 @default.
• W2971183932 hasConcept C2777583451 @default.
• W2971183932 hasConcept C2778041864 @default.
• W2971183932 hasConcept C2778729363 @default.
• W2971183932 hasConcept C2780580376 @default.
• W2971183932 hasConcept C3019892230 @default.
• W2971183932 hasConcept C71924100 @default.
• W2971183932 hasConcept C90924648 @default.
• W2971183932 hasConceptScore W2971183932C126322002 @default.
• W2971183932 hasConceptScore W2971183932C143998085 @default.
• W2971183932 hasConceptScore W2971183932C168563851 @default.
• W2971183932 hasConceptScore W2971183932C197934379 @default.
• W2971183932 hasConceptScore W2971183932C203092338 @default.
• W2971183932 hasConceptScore W2971183932C2776694085 @default.
• W2971183932 hasConceptScore W2971183932C2777063308 @default.
• W2971183932 hasConceptScore W2971183932C2777583451 @default.
• W2971183932 hasConceptScore W2971183932C2778041864 @default.
• W2971183932 hasConceptScore W2971183932C2778729363 @default.
• W2971183932 hasConceptScore W2971183932C2780580376 @default.
• W2971183932 hasConceptScore W2971183932C3019892230 @default.
• W2971183932 hasConceptScore W2971183932C71924100 @default.
• W2971183932 hasConceptScore W2971183932C90924648 @default.
• W2971183932 hasIssue "3" @default.
• W2971183932 hasLocation W29711839321 @default.
• W2971183932 hasLocation W29711839322 @default.
• W2971183932 hasOpenAccess W2971183932 @default.
• W2971183932 hasPrimaryLocation W29711839321 @default.
• W2971183932 hasRelatedWork W1986095564 @default.
• W2971183932 hasRelatedWork W1990419463 @default.
• W2971183932 hasRelatedWork W2107268345 @default.
• W2971183932 hasRelatedWork W2124201452 @default.
• W2971183932 hasRelatedWork W2162662700 @default.
• W2971183932 hasRelatedWork W2396141685 @default.
• W2971183932 hasRelatedWork W2401854143 @default.
• W2971183932 hasRelatedWork W2600847835 @default.
• W2971183932 hasRelatedWork W2606597291 @default.
• W2971183932 hasRelatedWork W4237418150 @default.
• W2971183932 hasVolume "56" @default.
• W2971183932 isParatext "false" @default.
• W2971183932 isRetracted "false" @default.
• W2971183932 magId "2971183932" @default.
• W2971183932 workType "article" @default.